Myomectomy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Myomectomy Market Trends and Insights

Growing Incidence of Uterine Fibroids Among Reproductive-Age Women

Fibroids now affect up to 70-80% of women by age 50, but the burden is most acute for those aged 25-44, the prime fertility window. Global surveillance recorded 9.6 million newly diagnosed cases in 2024.^{[1]Y. Zhang et al., “Global Trends in Uterine Fibroids Incidence,” cmj.org}African ancestry doubles to triple the risk, compelling healthcare systems to prioritize uterus-sparing options. United States payers already spend USD 34.4 billion annually on fibroid care, reinforcing surgical demand. As delayed childbirth trends intersect with higher fibroid prevalence, the myomectomy market continues to expand.

Rising Adoption of Minimally Invasive & Robotic-Assisted Surgeries

From 2013 to 2019, robotic procedures grew from 16.3% to 30.3% of total U.S. surgeries; gynecology accounted for a substantial share.^{[2]A. Reynolds et al., “Robotic Surgical Volumes 2013-2019,” ajog.org} The da Vinci 5 platform adds tactile feedback that lowers tissue trauma by 43%, addressing concerns over knot-tying accuracy and ergonomic strain. Nonetheless, capital outlays exceed USD 2 million per unit, and surgeons need 20–40 cases to achieve competence, slowing uptake in resource-constrained settings. Technical advantages, however, are gradually overriding cost hesitancy, feeding double-digit segment growth.

Increasing Fertility-Preservation Preference Delaying Hysterectomy

Prospective cohorts reveal similar quality-of-life outcomes for myomectomy and hysterectomy at 12 months, while pregnancy rates surpass 80% after minimally invasive myomectomy.^{[3]M. Bedient et al., “Fertility Outcomes after Myomectomy,” fertstert.org} These clinical gains align with societal shifts toward later motherhood, reinforcing myomectomy as a first-line surgical option even for large or multiple fibroids. Body-image and sexual-function scores further tilt patient choice toward uterus preservation, strengthening procedure volumes.

Emergence of Outpatient Reimbursement Models for ASC Procedures

Medicare’s 2025 Outpatient Prospective Payment System added separate payment ladders for laparoscopic and robotic myomectomy, narrowing hospital–ASC parity gaps. Private insurers typically reimburse 200% of Medicare, enabling ASCs to cover capital and staffing costs efficiently. Clinical data confirm safety equivalence: it means blood loss averages 192 mL and discharge occurs within 23 hours. Pandemic-era patient preference for short stay further propels ASC share.

High Cost of Advanced Laparoscopic & Robotic Systems

Hospitals face USD 2 million up-front costs plus maintenance when adopting robotic platforms, stretching capital budgets. Even with volume sharing, reaching economic break-even demands 150–200 annual cases. Emerging markets, where reimbursement is nascent, delay procurement and rely on conventional laparoscopy, restricting global diffusion.

Safety Concerns over Morcellation-Related Malignancy Spread

FDA advisories on power morcellation lowered usage rates until the bags, such as PneumoLiner, were contained and cleared. Trials record significant drops in peritoneal cell dissemination when containment is used. Nevertheless, additional device cost and longer operative time temper adoption, particularly for lower-resource centers.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Procedure Type: Robotic Precision Challenges Laparoscopic Dominance

Laparoscopic surgery maintained a 33.20% myomectomy market share in 2025, thanks to surgeon familiarity and broad availability. Robotic-assisted procedures, advancing at 9.46% CAGR, are eroding this lead by offering 3-dimensional vision and articulated instruments that simplify suturing in confined pelvic spaces. Abdominal open myomectomy persists for very large or numerous fibroids, but steadily declines as minimally invasive proficiency climbs. Hysteroscopic resection holds traction for submucosal fibroids, aided by improved single-use shavers that lessen fluid overload risk. Vaginal approaches remain niche, reserved for select posterior wall tumors.

Technological progress reinforces the shift: force-feedback sensors in next-generation robots decrease unintended tissue strain, while single-port laparoscopy enhances cosmesis for select cases. Training initiatives from professional societies are accelerating skilled labor supply, which in turn widens patient access to minimally invasive care across tertiary centers. The combined impact cements robots as a future mainstream modality within the myomectomy market.

By Product: Contained Morcellation Drives Innovation

In 2025, laparoscopic power morcellators represented 21.10% revenue, yet face heightened scrutiny. Contained tissue-removal systems are rising at 9.92% CAGR as surgeons adopt bag-in-bag devices that satisfy regulatory guidance. Energy and sealing platforms, such as advanced bipolar or ultrasonic generators, deliver fine thermal control, improving hemostasis and shortening operative duration. Knotless barbed sutures accelerate closure, while enhanced visualization stacks integrate near-infrared imaging to delineate vasculature.

Product pipelines emphasize safety first: bagged morcellators reduce parasitic tissue implantation, and modular energy devices minimize collateral thermal spread. Smaller form-factor cameras with 4K resolution assist depth perception. Ancillary disposables, although low in unit price, generate repeatable revenue streams and incentivize vendors to bundle full procedural kits, shaping procurement dynamics in the myomectomy market.

By End User: ASCs Challenge Hospital Dominance

Hospitals and clinics accounted for 31.20% of procedures in 2025, benefiting from comprehensive perioperative infrastructure and resident training capacity. ASCs are gaining 6.85% CAGR momentum, underpinned by shorter scheduling queues, predictable operating costs, and physician ownership models that align incentives. Specialty fertility centers carve out a growing sub-segment, blending reproductive endocrinology services with fertility-preserving surgery to offer an integrated patient pathway.

Outcomes data favor outpatient care when patient selection protocols are strictly adhered to; conversion to inpatient status remains below 2%. Pay-for-performance frameworks increasingly reimburse on bundled episodes, awarding efficiency and low complication rates. Consequently, ASCs will continue to siphon elective, low-acuity myomectomy cases away from inpatient settings.

Geography Analysis

North America led the myomectomy market size at 31.40% share in 2025 due to robust insurance coverage and the world’s highest concentration of robotic systems, over 6,000 installed units. Early adoption of FDA-cleared containment devices sustains minimally invasive momentum despite heightened morcellation scrutiny. Yet access inequity persists; Black women are 30% less likely than their counterparts to receive laparoscopic myomectomy even when clinically eligible. Federal and state programs are funding surgeon-training scholarships to narrow this gap.

Asia Pacific is forecast to post the fastest regional CAGR of 8.52% to 2031, propelled by national health-insurance expansions, rising middle-class expectations, and localized medical-device manufacturing. China’s domestic robot makers are filing for National Medical Products Administration approvals, aiming to lower unit costs by up to 35% relative to imported systems. Japan and South Korea maintain procedure volumes comparable to Western peers, while India and Indonesia prioritize capacity building with laparoscopic platforms first who.int. Professional exchanges, online simulation modules, and traveling fellowships are lifting surgical skill levels.

Europe retains steady growth under the harmonized Medical Device Regulation that guarantees high safety standards. Public health systems reimburse minimally invasive gynecology widely, though austerity policies limit robotic capital budgets in certain markets.

Middle East & Africa are nascent but promising; flagship hospitals in Saudi Arabia and South Africa have adopted robotic programs, often via public-private partnerships. Latin America shows moderate expansion; in Mexico’s public sector only 16.5% of fibroid procedures are laparoscopic, yet private institutions in Brazil have introduced comprehensive myomectomy centers that double as regional training hubs.

Regulatory Landscape

Regulatory pathways for myomectomy enabling devices vary by geography. In the United States, devices are routed through FDA CDRH processes with Premarket Notification (510(k)) or PMA, along with establishment registration and listing, and quality system compliance under the FDA Quality Management System Regulation (QMSR). A key anchor is the FDA stance on laparoscopic power morcellators, reinforced through safety communications and guidance directing use toward contained morcellation and validated performance testing when applicable, which in turn shapes labeling and containment strategy. In Europe, market access is governed by EU MDR 2017/745 and notified-body conformity assessment, with higher-risk technologies requiring clinical data and post-market surveillance. ISO standards such as ISO 13485 and sterilization requirements also influence design controls and documentation across regions.

Value Chain Analysis

The value chain starts with suppliers of surgical-grade materials such as stainless steels, polymers, and precision optics, along with specialized components used in energy generators, camera stacks, and robotic accessories. It then moves to OEMs that integrate systems and disposables used across laparoscopic, hysteroscopic, and robotic-assisted myomectomy. Core OEM participants in this ecosystem include Intuitive Surgical (robotic systems), Medtronic (energy and robotic platform development), Hologic (gynecology portfolio including tissue removal and fibroid solutions), and CooperSurgical (gynecology devices and consumables). Manufacturing and final assembly rely on validated processes, including sterilization and packaging controls for sterile disposables. Quality agreements and supplier controls carry outsized weight because many kits combine reusable capital equipment with single-use components.

Commercialization is split between direct-to-facility sales and channel-led distribution. Group purchasing organization contracting and hospital standardization shape purchasing decisions, while recurring revenue is supported by procedure-based consumables, including containment bags, shavers, sutures, and energy handpieces. Key bottlenecks include single-source dependencies for advanced imaging sensors and delays in service or spare-parts availability for visualization and robotic subsystems, which can affect uptime in hospitals and ambulatory surgical centers.

Market Opportunities and Future Outlook

A major whitespace is the continued shift from uncontained to validated contained tissue extraction across both laparoscopic morcellation workflows and newer integrated containment-and-extraction concepts. In July 2026, Claria Medical received FDA De Novo marketing authorization for the Claria System, an integrated uterine tissue containment and extraction device, which reinforces labeling and workflow requirements relevant to tissue containment. It also creates room for adjacent product offerings aimed at addressing dissemination concerns.

Another opportunity is expanding robotic access for gynecologic procedures beyond large tertiary hospitals, supported by regulatory filings, clinical evidence generation, and ASC-centric positioning. In April 2026, Distalmotion disclosed an FDA submission to expand US indications for the DEXTER Robotic Surgery System and noted an IDE for a US myomectomy clinical trial. In March 2026, Hospital Israelita Albert Einstein described feasibility of Hugo RAS use in myomectomy with contained cold-scalpel morcellation and transvaginal specimen extraction. Together, these signals point to differentiated offerings around smaller-footprint robotics, training and service bundling, and outpatient-oriented procedure pathways where reimbursement mechanisms and operational efficiency influence adoption decisions.